Status:
COMPLETED
A Study of Lenvatinib in Combination With Pembrolizumab in Korean Patients
Lead Sponsor:
Eisai Korea Inc.
Conditions:
Endometrial Neoplasms
Endometrium
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to collect and evaluate the following information in relation to the safety and the efficacy of Lenvatinib in lenvatinib/pembrolizumab combination therapy in the post mark...
Eligibility Criteria
Inclusion
- Greater than (\>) 18 years
- Considered by the treating physician for lenvatinib/pembolizumab combination therapy for the approved indications in Korea, prior to study
- Provided written consent for use of personal medical information for the study purpose
- Meets the approved indication and none of the contraindications for lenvatinib/pembrolizumab combination therapy in Korea, as confirmed by the treating physician
Exclusion
- 1\. Currently receiving lenvatinib and pembrolizumab as part of a clinical trial
Key Trial Info
Start Date :
June 25 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 7 2023
Estimated Enrollment :
135 Patients enrolled
Trial Details
Trial ID
NCT05375136
Start Date
June 25 2021
End Date
November 7 2023
Last Update
March 25 2024
Active Locations (19)
Enter a location and click search to find clinical trials sorted by distance.
1
Eisai Site #04
Bundang, South Korea
2
Eisai Site #02
Busan, South Korea
3
Eisai Site #10
Busan, South Korea
4
Eisai Site #17
Busan, South Korea